Your session is about to expire
← Back to Search
Masitinib for Severe Mast Cell Activation Syndrome
Study Summary
This trial is testing the effectiveness and safety of two different doses of masitinib, compared to placebo, in treating patients with severe MCAS who have not responded well to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 3 trial • 463 Patients • NCT00113763Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been on a stable dose of Anti-H1 medication for at least 4 weeks.I have severe itching, frequent hot flashes, or significant depression.I've tried at least two treatments for my condition without success in the last two years.I have a slow-growing form of mastocytosis affecting my whole body.I have been treated with a Tyrosine Kinase Inhibitor before.I haven't changed my MCAS treatment or started any new one in the last 4 weeks.I have been diagnosed with mast cell activation syndrome.I am not pregnant or breastfeeding.
- Group 1: Masitinib (6.0) & BSC
- Group 2: Placebo & BSC
- Group 3: Masitinib (4.5) & BSC
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Best supportive care?
"Best supportive care has been assigned a safety rating of 2, given that there is some evidence confirming it's security but none showing its effectiveness."
Is it possible to still apply for participation in this research endeavor?
"Affirmative, clinicaltrials.gov confirms that this medical experiment was posted on July 1st 2022 and is currently recruiting for 72 participants from a single site."
Am I eligible to enroll in this research study?
"This clinical trial is open to patients who have been diagnosed with mast cell activation syndrome and are between the ages of 18 and 75. A maximum of 72 individuals will be accepted into this medical experiment."
Could persons of advanced age participate in this experiment?
"The participants of this trial must be aged between 18-75. For those under the age of 18, there are 377 studies available and for a person over 65 years old, 995 studies can be found."
How many participants are being accepted into this research project?
"Affirmative. Per clinicaltrials.gov, this medical study is currently recruiting participants and was first posted on July 1st of 2022 with its last update occurring on the 18th of that same month. The goal is to enrol 72 patients at a single site."
Share this study with friends
Copy Link
Messenger